ロード中...
Cabozantinib for the treatment of kidney cancer
INTRODUCTION: Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. AREAS COVERE...
保存先:
| 出版年: | Expert Rev Anticancer Ther |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166873/ https://ncbi.nlm.nih.gov/pubmed/28633552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737140.2017.1344553 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|